Osteoarthritis program
Osteoarthritis
Key Facts
About Risen Pharma Tech
Clinical-stage biotech developing small molecule and siRNA drugs for osteoarthritis, oncology, and Alzheimer's disease with international competitiveness.
View full company profileAbout OrthoSera
OrthoSera is a Budapest-based regenerative medicine company pioneering the therapeutic use of blood serum and its components, particularly albumin, to activate stem cells and enhance tissue regeneration. Its lead product, BoneAlbumin—a serum albumin-enhanced bone allograft—has been in clinical use since 2015 with supporting long-term data. The company is developing a pipeline targeting osteoarthritis and skin rejuvenation while also applying its plasma expertise to areas like convalescent serum therapy. It maintains a fully integrated, quality-certified manufacturing and R&D operation.
View full company profileAbout Orthros Medical
Orthros Medical is a private, preclinical-stage biotech leveraging the unique properties of VHH antibodies to develop targeted therapies and diagnostics. The company's core focus is on osteoarthritis, aiming to create locally administered treatments that could offer advantages over conventional options. It operates through strategic partnerships, such as with Animalcare and the University of Twente, and is exploring opportunities across human and veterinary markets. The company appears to be pre-revenue, advancing its platform and pipeline through collaborations.
View full company profileAbout Britecyte
Britecyte is a private, Seattle-based biotech founded in 2016, developing regenerative therapies based on its proprietary platform for non-immunogenic allogeneic adipose tissue. The company has two initial commercial products, Liposana and Lipoderma, for soft tissue restoration, and is exploring pipeline applications in metabolic diseases and osteoarthritis. Operating as a therapeutics company, Britecyte appears to be in an early commercial or pre-revenue stage, leveraging its scientific breakthrough to create ready-to-use adipose allografts that overcome the limitations of autologous tissue transfer.
View full company profileTherapeutic Areas
Other Osteoarthritis Drugs
| Drug | Company | Phase |
|---|---|---|
| MSC‑OA | Advancells | Phase 1 |
| ViscoCell™ for Osteoarthritis | Likarda | Pre-clinical |
| Osteoarthritis Biologic Therapy | Ageless Biotech | Phase 2b |
| PKM-011 | PK MED | Pre-clinical |
| CYT-108 | Cytonics | Phase 2 |
| Topical PSGAG | ADORA Life Science | Pre-clinical |
| FGF18 Gene Therapy | Remedium Bio | Pre-clinical |
| MOTYS™ | Doron Therapeutics | Phase 3 |
| Osteoarthritis Treatment Program | Biovico | Pre-clinical |
| aGF | Scarcell Therapeutics | Phase 1 |
| Cartilage Repair | Sayenza Biosciences | Clinical |
| BRM521 | BRIM Biotechnology | Preclinical |